SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.

García-Marcos, L; Asher, MI; Pearce, N; Ellwood, E; Bissell, K; Chiang, C-Y; El Sony, A; Ellwood, P; Marks, GB; Mortimer, K; et al. García-Marcos, L; Asher, MI; Pearce, N; Ellwood, E; Bissell, K; Chiang, C-Y; El Sony, A; Ellwood, P; Marks, GB; Mortimer, K; Martínez-Torres, AE; Morales, E; Perez-Fernandez, V; Robertson, S; Rutter, CE; Silverwood, RJ; Strachan, DP; Global Asthma Network Phase I Study Group (2022) The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study. Eur Respir J, 60 (3). ISSN 1399-3003 https://doi.org/10.1183/13993003.02866-2021
SGUL Authors: Strachan, David Peter

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (6MB) | Preview
[img]
Preview
PDF (Supplementary tables and figures) Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview

Abstract

AIMS: There have been no worldwide standardised surveys of prevalence and severity of asthma, rhinoconjunctivitis and eczema in school children for 15 years. The present study aims to provide this information. METHODS: Following the exact International Study of Asthma and Allergies in Childhood (ISAAC) methodology (cross-sectional questionnaire-based survey), Global Asthma Network (GAN) Phase I was carried out between 2015 and 2020 in many centres worldwide. RESULTS: The study included 157 784 adolescents (13-14 years of age) in 63 centres in 25 countries and 101 777 children (6-7 years of age) in 44 centres in 16 countries. The current prevalence of symptoms, respectively, was 11.0% and 9.1% for asthma, 13.3% and 7.7% for rhinoconjunctivitis and 6.4% and 5.9% for eczema. The prevalence of asthma ever was 10.5% and 7.6%, hay fever ever was 15.2% and 11.1% and eczema ever was 10.6% and 13.4%, respectively. Centres in low or lower middle gross national income countries (LICs or LMICs) had significantly lower prevalence of the three disease symptoms and diagnoses (except for hay fever). In children, the prevalence of asthma and rhinoconjunctivitis symptoms was higher in boys, while the reverse occurred among adolescents. For eczema, while the prevalence among female adolescents was double that of males, there was no sex difference among children. Centre accounted for non-negligible variability in all disease symptoms (10-20%). CONCLUSION: The burdens of asthma, rhinoconjunctivitis and eczema vary widely among the limited number of countries studied. Although symptom prevalence is lower in LICs and LMICs, it represents a considerable burden everywhere studied.

Item Type: Article
Additional Information: Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Keywords: Adolescent, Asthma, Child, Conjunctivitis, Cross-Sectional Studies, Eczema, Female, Humans, Hypersensitivity, Male, Prevalence, Rhinitis, Allergic, Seasonal, Surveys and Questionnaires, Global Asthma Network Phase I Study Group, Humans, Asthma, Conjunctivitis, Eczema, Hypersensitivity, Prevalence, Cross-Sectional Studies, Adolescent, Child, Female, Rhinitis, Allergic, Seasonal, Male, Surveys and Questionnaires, 11 Medical and Health Sciences, Respiratory System
SGUL Research Institute / Research Centre: Academic Structure > Population Health Research Institute (INPH)
Journal or Publication Title: Eur Respir J
ISSN: 1399-3003
Language: eng
Dates:
DateEvent
15 September 2022Published
10 February 2022Published Online
19 January 2022Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
Projects:
Project IDFunderFunder ID
MR/N013638/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
668954Seventh Framework Programmehttp://dx.doi.org/10.13039/501100004963
PI17/0170Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
16/136/35National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
PI17/00179Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PI17/00694Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PI17/00756Instituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PRIMVAL 17/01 y 18/01Instituto de Investigación Sanitaria ValdecillaUNSPECIFIED
GRS 1239b/16Gerencia Regional de Salud de la Junta de Castilla y LeónUNSPECIFIED
PubMed ID: 35144987
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114111
Publisher's version: https://doi.org/10.1183/13993003.02866-2021

Actions (login required)

Edit Item Edit Item